An improved synthesis of m-Hydroxymexiletine, a potent mexiletine metabolite

Drug Metabolism Letters

Volumn 6, Issue 2, 2012, Pages 124-128

  Catalano, Alessia ^a   Carocci, Alessia ^a   Lentini, Giovanni ^a   Defrenza, Ivana ^a   Cavalluzzi, Maria Maddalena ^a   Franchini, Carlo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Anti arrhythmics; hNav1.4; hNav1.5; Hydroxylation; M Hydroxymexiletine; Metabolite switch; Sodium channel blockers

Indexed keywords

3 CHLOROPERBENZOIC ACID; 3 HYDROXYMEXILETINE; ANTIARRHYTHMIC AGENT; DRUG METABOLITE; MEXILETINE; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; HUMAN; HUMAN CELL; IC 50; MELTING POINT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTI-ARRHYTHMIA AGENTS; HEK293 CELLS; HUMANS; MEXILETINE; NAV1.4 VOLTAGE-GATED SODIUM CHANNEL; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; STEREOISOMERISM; VOLTAGE-GATED SODIUM CHANNEL BLOCKERS;

EID: 84876696198     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231212804096691     Document Type: Article

References (30)

1. Yamauchi, M.; Watanabe, E.; Yasui, K.; Takeuchi, H.; Terasawa T.; Sawada, K.; Hishida, H.; Kodama, I. Prevention of ventricular extrasystole by mexiletine in patients with normal QT intervals is associated with a reduction of transmural dispersion of repolarization. Int. J. Cardiol., 2005, 103, 92-97.
2. Fenster, P.E.; Comess, K.A. Evaluations of new drugs. Pharmacotherapy, 1986, 6, 1-9.
3. Sloan, P.; Basta, M.; Storey, P.; von Gunten, C. Mexiletine as an adjuvant analgesic for the management of neuropathic cancer pain Anesth. Analg., 1999, 89, 760-761.
4. Jarvis, B.; Coukell, A.J. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs, 1998, 56, 691-707.
5. Oskarsson, P.; Ljiunggren, J.-G.; Lins, P.-E. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. Diabetes Care, 1997, 20, 1594-1597.
6. Tremont-Lukats, I.W.; Challapalli, V.; McNicol, E.D.; Lau, J.; Carr, D.B. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth. Analg., 2005, 101, 1738-1749.
7. Rüdel, R.; Lehmann-Horn, F. Membrane changes in cells from myotonia patiens. Physiol. Rev., 1985, 65, 310-356.
8. Lehmann-Horn, F.; Jurkat-Rott, K. Voltage-gated ion channels and hereditary disease. Physiol. Rev., 1999, 79, 1317-1372.
9. Cannon, S.C. Voltage-gated ion channelophaties of the nervous system. Clin. Neurosci. Res., 2001, 1, 104-117.
10. Gay, S.; Dupuis, D.; Faivre, L.; Masurel-Paulet, A.; Labenne, M.; Colombani, M.; Soichot, P.; Huet, F.; Hainque, B.; Sternberg, D.; Fontaine, B.; Gouyon, J.-B.; Thuvin-Robinet, C. Severe neonatal nondistrophic myotonic secondary to a novel mutation of the voltage-gated sodium channel (SCN4A) gene. Am. J. Med. Genet. A., 2008, 146A, 380-383.
11. Akinci, E.; Yüzbaşioglu, Y.; Coşkun, F. Hemodialysis as an alternative treatment of mexiletine intoxication. Am. J. Emerg. Med., 2011, 29, 1235-1236.
12. Catalano, A.; Carocci, A.; Fracchiolla, G.; Franchini, C.; Lentini, G.; Tortorella, V.; De Luca, A.; De Bellis, M.; Desaphy, J.-F.; Conte Camerino, D. Stereospecific synthesis of para-hydroxymexiletine and sodium channel blocking activity evaluation. Chirality, 2004, 16, 72-78.
13. Cavalluzzi, M.M.; Catalano, A.; Bruno, C.; Lovece, A.; Carocci, A.; Corbo, F.; Franchini, C.; Lentini, G.; Tortorella, V. Synthesis of (R)-, (S)-, and (RS)-hydroxymethylmexiletine, one of the major metabolites of mexiletine. Tetrahedron: Asymmetry, 2007, 18, 2409-2417.
14. De Bellis, M.; De Luca, A.; Rana, F.; Cavalluzzi, M.M.; Catalano, A.; Lentini, G.; Franchini, C.; Tortorella, V.; Conte Camerino, D. Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents. Br. J. Pharmacol., 2006, 149, 300-310.
15. Catalano, A.; Carocci, A.; Cavalluzzi, M.M.; Di Mola, A., Lentini, G., Lovece, A.; Dipalma, A.; Costanza, T., Desaphy, J.-F.; Conte Camerino, D.; Franchini, C. Hydroxylated analogs of mexiletine as tools for structural-requirements investigation of the sodium channel blocking activity. Arch Pharm. Chem. Life Sci., 2010, 343, 325-332.
16. Catalano, A.; Lentini, G.; Carocci, A.; Di Mola, A.; Bruno, C.; Desaphy, J.-F.; Carbonara, R.; Conte Camerino, D.; De Palma, A.; Budriesi, R.; Ghelardini, C.; Perrone, M.G.; Colabufo, N.A.; Franchini, C. Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels. J. Med. Chem., 2012, 55, 1418-1422.
17. Grech-Bélanger, O.; Turgeon, J.; Lalande, M.; Bélanger, P.M. Meta-hydroxymexiletine, a new metabolite of mexiletine. Drug. Metab. Dispos., 1991, 19, 458-461.
18. Tucker, G.T. Chiral switches. Lancet, 2000, 355, 1085-1087.
19. Desaphy, J.-F.; Dipalma, A.; Costanza, T.; Carbonara, R.; Di Nardo, M.M., Catalano, A.; Carocci, A.; Lentini, G.; Franchini, C.; Conte Camerino D. Molecular insights into the local anesthetic receptor within voltage-gated sodium channels using hydroxylated analogs of mexiletine. Front. Pharmacol., 2012, 3, 1-12.
20. Still, W.C.; Kahn, M.; Mitra, A. Rapid chromatographic technique for preparative separations with moderate resolution. J. Org. Chem., 1978, 43, 2923-2925.
21. Carocci, A.; Catalano, A.; Corbo, F.; Duranti, A., Amoroso, R.; Franchini, C., Lentini, G.; Tortorella, V. Stereospecific synthesis of mexiletine and related compounds: Mitsunobu versus Williamson reaction. Tetrahedron: Asymmetry, 2000, 11, 3619-3634.
22. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis, 1981, 1-28.
23. Màtyus, P.; Rettegi, T.; Varrò, A.; Papp, J.G. New antiarrhythmic agents: a conceptually novel approach. Med. Res. Rev., 2000, 20, 294-303.
24. Anwer, M.K.; Sherman, D.B.; Roney, J.G.; Spatola, A.F. Applications of ammonium formate catalytic transfer hydro-genation. 6. Analysis of catalyst, donor quantity, and solventeffects upon the efficacy of dechlorination. J. Org. Chem., 1989, 54, 1284-1289.
25. Franklin, R.; Golding, B.T.; Tyson, R.G. Mexiletine amino acid and peptide prodrugs and uses thereof. W.O. Patent 2010149760, December 29, 2010.
26. Turgeon, J.; Uprichard, A.C.G.; Belanger, P.M.; Harron, D.W.G.; Grech-Belanger, O. Resolution and electrophysiological effects of mexiletine enantiomers. J. Pharm. Pharmacol., 1991, 43, 630-635.
27. Hill, R.J.; Duff, H.J.; Sheldon, R.S. Determinants of stereospecific binding of type I antiarrhythmic drugs to cardiac sodium channels. Mol. Pharmacol., 1988, 34, 659-663.
28. De Luca, A.; Natuzzi, F.; Lentini, G.; Franchini, C.; Tortorella, V., Conte Camerino, D. Stereoselective effects of mexiletine enantiomers on sodium currents and excitability characteristics of adult skeletal muscle fibers. Naunyn-Schmiedebergs Arch. Pharmacol., 1995, 352, 653-661.
29. De Luca, A., Natuzzi, F.; Falcone, G.; Duranti, A.; Lentini, G., Franchini, C., Tortorella, V., Conte Camerino, D. Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide. Naunyn-Schmiedebergs Arch. Pharmacol., 1997, 356, 777-787.
30. De Luca, A.; Natuzzi, F.; Desaphy, J.-F., Loni, G.; Lentini, G.; Franchini, C.; Tortorella, V.; Conte Camerino, D. Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels. Mol. Pharmacol., 2000, 57, 268-277.